ABSTRACT SUBMISSION ANNOUNCEMENT

Oral Presentation

Abstract ID

Topic

Category

Award (THB)

Presentation Date

Session Time

Time Slot

Location

56

EXPANDING THE UNIVERSE OF ACTIONABLE NEOANTIGENS THROUGH DEEP LEARNING AND HUMAN LEUKOCYTE ANTIGEN PEPTIDOMICS

General

10,000

August 9, 2019

10:30 - 11:30

10:30 - 10:40

Lotus 1-2

68

IDENTIFICATION OF ANAPLASTIC LYMPHOMA KINASE-EXPRESSING LUNG ADENOCARCINOMA BY NEWLY-DEVELOPED ULTRASHORT RT-PCR ASSAY

General

10,000

August 9, 2019

10:30 - 11:30

10:40 - 10:50

Lotus 1-2

66

CHIMERIC ANTIGEN RECEPTOR T CELLS AGAINST BREAST CANCER CELLS BY TARGETING FOLATE RECEPTOR ALPHA PROTEIN

General

2,500

August 9, 2019

10:30 - 11:30

10:50 - 11:00

Lotus 1-2

69

POTENTIAL ROLE OF CARBOHYDRATE RESPONSE ELEMENT BINDING PROTEIN IN NON-SMALL CELL LUNG CANCER

Trainee

10,000

August 9, 2019

10:30 - 11:30

11:00 - 11:07

Lotus 1-2

43

EVALUATION OF GLUCOSE TOLERANCE IN HIGH DOSE RADIOACTIVE IODINE-131 TREATED THYROID CARCINOMA PATIENTS

Trainee

5,000

August 9, 2019

10:30 - 11:30

11:07 - 11:14

Lotus 1-2

37

RETROSPECTIVE ANALYSIS OF FACTORS INFLUENCING THE DECISION BETWEEN INPATIENT OR OUTPATIENT RADIOACTIVE IODINE ABLATION/TREATMENT OF PAPILLARY THYROID MICROCARCINOMA

Trainee

2,500

August 9, 2019

10:30 - 11:30

11:14 - 11:21

Lotus 1-2

51

THE MIR-483-5P AS A MARKER PREDICTING CHEMORESISTANCE IN EPITHELIAL OVARIAN CANCER KEYWORDS: MIR-483-5P, CHEMORESISTANCE, OVARIAN CANCER

Trainee

2,500

August 9, 2019

10:30 - 11:30

11:21 - 11:28

Lotus 1-2

E-Poster Presentation

Abstract ID

Topic

Category

Award

Presentation Date

Session Time

Time Slot

Location

33

VALUE OF SUPERB MICROVASCULAR IMAGING (SMI) IN CHARACTERIZING OF NODULAR TYPE FOCAL FAT SPARING LESION, BENIGN NODULE, AND MALIGNANCY IN THE BACKGROUND OF FATTY LIVER.

Trainee

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

39

SONOGRAPHIC APPEARANCE OF DETECTED LIVER NODULES IN LONG-TERM HEPATITIS B SURVEILLANCE PROGRAM

Trainee

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

40

STRATIFYING RISK OF DEVELOPING HCC IN HBV INFECTION PATIENTS BY CLINICAL STAGES OF THE DISEASE MAY HELP OPTIMIZE SURVEILLANCE INTERVALS: A LONG-TERM COHORT STUDY

Trainee

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

50

CLINICAL FEATURES OF PARANEOPLASTIC NEUROLOGICAL SYNDROME RELATED TO ANTI-RI (ANNA2): THAI CASE SERIES AND REVIEW OF THE LITERATURES

Trainee

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

52

MYCOPHENOLIC ACID AS A POTENTIAL DRUG FOR THE TREATMENT OF OSTEOSARCOMA

General

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

57

USE OF P16/KI67 FOR TRIAGE OF CERVICAL INTRAEPITHELIAL NEOPLASIA II-III IN PATIENTS INFECTED WITH HIGH RISK TYPE OF HUMAN PAPILLOMA VIRUS (HPV)

General

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

62

ANTI-TUMOR EFFECT OF ANTI-CD133 CHIMERIC ANTIGEN RECEPTOR T CELLS AGAINST CHOLANGIOCARCINOMA CELLS

General

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

63

IDENTIFICATION AND CHARACTERIZATION OF NOVEL HUMAN SINGLE CHAIN VARIABLE FRAGMENT AGAINST CD19 FOR ENGINEERED T CELL THERAPY

General

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

65

TISSUE SPECIFIC MICRORNA MEAN EXPRESSION IN LIPOSARCOMA AND LIPOMA

General

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

72

RECURRENT COLORECTAL CANCER: CLINICAL PRESENTATION AND MODE OF DETECTION

Trainee

Consolation prize

To be announced
Please see e-poster development file and submission guideline at the bottom of this page

E-Poster Display

Abstract ID

Topic

Category

E-Poster Display Preparation Guide

32

PRELIMINARY OUTCOME OF MINIMALLY INVASIVE SPINAL SURGERY IN SPINAL METASTASIS PATIENTS: CHULABHORN HOSPITAL EXPERIENCE

General

Thank you for your submission of abstract for the Princess Chulabhon International Oncology Conference 2019 at Centara Grand & Bangkok Convention Centre at CentralWorld, Bangkok, Thailand, slated for August 8-9, 2019. The scientific steering committees have reviewed number of abstracts, and we are delighted to inform you that your paper was accepted to be an E-poster Display. For those whose papers are accepted for E-poster Display – will not require to present their poster at the conference. However, their abstracts will be published in the conference e-book and the scientific committee also encourage the submitters to develop an E-poster file to display at the E-poster station at the conference.
See e-poster development file and submission guideline at the bottom of this page.

34

POSTOPERATIVE OUTCOMES OF SUBAXIAL CERVICAL SPINE METASTASES: A COMPARISON OF THE ANTERIOR, POSTERIOR AND COMBINED APPROACH.

General

35

THE EFFECTIVENESS AND SAFETY OF ULTRA-LONG NAVIGATED MINIMALLY INVASIVE PALLIATIVE SPINE SURGERY IN EXTENSIVE SPINAL METASTASIS.

General

36

NON-FUSION PALLIATIVE SPINE SURGERY WITHOUT ANTERIOR RECONSTRUCTION IS SAFE AND IMPROVING QUALITY-OF-LIFE IN SPINAL METASTASES PATIENTS

General

38

UNIQUE CHARACTERISTICS AND PROGNOSIS OF MET EXON14 SPICE-SITE MUTATION AND CO-MUTATION IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS

General

45

FACTORS OF EXCLUSIVE BREASTFEEDING FOR BREAST CANCER PREVENTION AT PESAWAHAN VILLAGE, PORONG, SIDOARJO - INDONESIA, MAY 2018

General

46

PREVALENCE AND ASSOCIATION FACTORS OF DEPRESSION AND ANXIETY IN HEAD AND NECK CANCER PATIENTS

General

47

ASSOCIATION BETWEEN QUANTITY OF ADIPOSE-DERIVED STEM CELLS AND DEMOGRAPHIC FACTORS IN BREAST CANCER PATIENTS

General

48

SOLID/TRABECULAR VARIANT PAPILLARY THYROID CARCINOMA IN A 10-YEAR-OLD GIRL WITH AUTOIMMUNE THYROID DISEASE

Trainee

49

TAI CHI AND CARDIAC HEALTH, EJECTION FRACTION AMONG CANCER PATIENTS : A PILOT STUDY (TICHEFCAP)

General

53

DOES PROSTHETIC RECONSTRUCTION HAVE BETTER SURVIVAL THAN BIOLOGIC IN LIMB SPARING TUMOR SURGERY?

General

54

EXPRESSION LEVELS OF MIR-34-FAMILY MICRORNAS ARE ASSOCIATED WITH TP53 MUTATION STATUS IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

General

58

PROLINE-RICH HOMEODOMAIN PROTEIN MIGHT SERVE AS A PROGNOSTIC MARKER OF CHOLANGIOCARCINOMA AND INDICATES SENSITIVITY TO ADENOSINE.

General

60

STRENGTHENING CERVICAL CANCER PREVENTION THROUGH BEHAVIORAL ECONOMICS INTERVENTIONS IN CLINICAL PRACTICE.

General

61

GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING MUCIN 1 AGAINST CHOLANGIOCARCINOMA

General

64

CHIMERIC ANTIGEN RECEPTOR T CELLS TARGETING ΑVΒ6 INTEGRIN FOR CHOLANGIOCARCINOMA

General

70

SQUAMOUS CELL CARCINOMA OVER CORNEA AFTER DIAGNOSIS OF NON-HODGKIN LYMPHOMA

Trainee

71

PROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND RISK FACTOR FOR CHOLANGIOCARCINOMA

General

73

ANTIPROLIFERATIVE ASSESSMENT INDUCED BY LEAF EXTRACTS OF ANDROGRAPHIS PANICULATA, ZIZIPHUS SPINA-CHRISTI AND VERNONIA EXTENSA ON CANCER CELL LINES

General

Download E-Poster Preparation Guideline:

PRESENTATION GUIDELINE

Speakers’ Presentation

PowerPoint slide format:

Room Format Download Sample Slide
Convention Hall A 16:9 DOWNLOAD
Lotus Room 4:3 DOWNLOAD

 

Speakers and oral presenters are requested to upload PowerPoint slide presentations at the Slide Preview Room at least 1 hour prior to your session. There will be a technician available to assist you.

Speaker Room and Slide Preview Room

 

Data Presentation: For PowerPoint presentations (or any other PC based applications), please bring your presentation on a USB Memory stick and load it on one of the conference computers in the Slide Preview Room at least 1 hour before the start of your session. Kindly remember when preparing your PowerPoint slides, that the font size should be large enough (at least 28) so that when projected it can be seen from the rear of the session hall. Please also remember that your PowerPoint slide presentation should be prepared in a landscape format.

If including videos in your presentation, please make sure to check that they work in the Slide Preview Room and also in the session hall where your lecture is taking place (during a coffee or lunch break at least 30 minutes prior to your session.

Please note that the conference computers in the session halls are being supplied with Office 2013 (at least).

Although not recommended, you may supply your own laptop computer. In such a case, please confirm that it has a suitable VGA socket for external signal. Please check it first in the Slide Preview Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break at least 30 minutes prior to your session.

Important note for Macintosh users:

In order to use a Mac presentation on a PC compatible computer, please note that you need to prepare it according to the instructions below, before bringing it to the Slide Preview Room:

  1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).
  2. Insert pictures as JPG files (and not TIF, PNG or PICT – these images will not be visible on a PowerPoint based PC).
  3. Use a common movie format, such as AVI, MPG and WMV. MOV files from QuickTime will not be visible on a PowerPoint based PC.

Alternatively, you may use your own Macintosh laptop computer. In such a case please provide a VGA adaptor for external signal, advise the operators in the Slide Preview Room as soon as you arrive, and test it in the session hall where your lecture is taking place during the coffee or lunch break at least 30 minutes prior to your session.

 Please note that VHS Video projection, 35 mm’ slide projection and Overhead projection (projection of transparencies) will not be available.

At the Session Hall

  • Assemble in your session room at least 10 minutes before the beginning of the session.
  • Please check the final program to confirm the date, time, room and order of your presentation.
  • Ensure that you sit near the front of the room with easy access to the stage.
  • Ensure that you keep to the time allocated to you, as it will cause disruption to sessions if you run over your allotted time.
  • If there are any changes or corrections required to the presentation details, please let the Technician know as soon as possible.

REGISTRATION